S
ince the original descriptions of the role of stromal cell-derived factor (SDF)-1 in recruiting bone marrow derived stem cells to the sites of vascular 1 and myocardial injury, 2 there has been increasing evidence of the broader importance of the SDF-1:CXCR4 axis in regulating myocardial repair following ischemic injury. [2] [3] [4] [5] [6] In this issue of Circulation Research, Tang et al investigate the role of the SDF-1:CXCR4 axis in the recruitment of exogenously derived cardiac stem cells. 7 They further investigate how cardiac stem cell exposure to hypoxia before their intravenous administration alters cardiac stem cell engraftment and subsequent effects on myocardial repair.
Cardiac stem cells were derived from cardiosphere cultures and were defined by as CLK (cardiosphere-derived c-Kit In vitro studies demonstrated that CLK cells grown under normoxic conditions did not migrate significantly in response to SDF-1, nor was there significant engraftment of functional effects of these cells following the intravenous administration 1 hour after acute myocardial infarction. Conversely, culturing the CLK cells for 6 hours before harvest and infusion led to robust migration of the CLK cells in response to SDF-1 in vitro. Furthermore, the hypoxia treatment led to significant migration and engraftment of CLK cells following intravenous infusion and significant functional effects including decreased infarct size, increased vascular growth, and improved cardiac function.
Several lines of evidence are offered, suggesting that the upregulation of CXCR4 in response to hypoxia is responsible for the increased CLK cell migration and engraftment. Protein array analysis demonstrated that hypoxia induced CXCR4 expression; immunofluorescence and flow cytometry showed the CXCR4 expression was at the surface of the CLK cells. Upregulation of cellular hypoxia-inducible factor-1␣ expression preceded the upregulation of CXCR4, and inhibition of hypoxia-inducible factor-1␣ with short hairpin RNA inhibited the increase in CXCR4 expression, as well as the enhanced migration of the hypoxia treated CLK cells. Finally, the cotreatment of CLK cells with hypoxia and AMD-3100, a CXCR4 antagonist, inhibited the migration of CLK cells in response to SDF-1 in vitro, as well as the engraftment of CLK cells following intravenous infusion in vivo. The inhibition of CLK cell engraftment through the inhibition of the SDF-1:CXCR4 axis completely inhibited any of the functional benefits that were observed following the administration of hypoxia-treated CLK cells.
The data from this study demonstrate the importance of the SDF-1:CXCR4 axis in stem cell recruitment to the heart following myocardial infarction. Less clear is the mechanism of benefit associated with the engraftment of the hypoxia treated CLK cells and whether hypoxia led to improved functional effects beyond just improving stem cell homing and engraftment. The exposure of CLK cells to hypoxia resulted in an approximate 3-fold increase in SDF-1 protein expression. We have previously demonstrated that constitutively increasing SDF-1 expression approximately 3-fold in mesenchymal stem cells leads to significant reduction in cardiac myocyte death, increased vascular density, and improvement in cardiac function following the intravenous infusion of mesenchymal stem cells 24 hours after myocardial infarction. 8 Thus, it is likely that the hypoxic pretreatment of CLK cells leads not only to improved CLK homing and engraftment but also may render the CLK cells more potent.
The field of cell based cardiac repair has arguably struggled with defining key molecular mechanisms that underlie myocardial repair in response to cell therapy. These data from Tang et al 7 build on the growing body of literature that suggests the following testable hypothesis: stem cell-based repair of the heart is mediated through the temporal alignment of the SDF-1:CXCR4 axis.
Within minutes to an hour after myocardial infarction, SDF-1 is expression is rapidly upregulated in heart, providing a signal to which stem cells can be recruited. 2 However, as shown by Tang et al, stem cells have to express CXCR4 to home and engraftment in the heart. 7 Although bone marrowderived stem cells express CXCR4, the bone marrow cells need to be mobilized and apparently mature before having functional effects. A multivariate analysis of the REPAIR-AMI trial, 9 which randomized patients to placebo or autologous bone marrow mononuclear cell infusion down the infarct related vessel, showed that when magnitude of SDF-1 migration was included as a variable, treatment time following myocardial infarction was no longer a predictor of response to therapy. These data suggest that cells in the bone marrow alter their responsiveness to SDF-1 over time, indicating that cell 4 to 7 days after myocardial infarction may be more responsive to SDF-1 than bone marrow cells at baseline. The difficulty here, as suggested in the Figure, is that SDF-1 expression in the heart is declining by 4 to 7 days after myocardial infarction. 2 Thus, harvesting bone marrow mononuclear cells and infusing them into the infarct-related vessel days after a myocardial infarction may be presenting CXCR4-expressing, SDF-1-responsive bone marrow mononuclear cells to the heart at a time of declining in myocardial SDF-1 expression. Without this intervention, the SDF-1-responsive bone marrow mononuclear stem cells might be mobilized at a time when myocardial SDF-1 expression is not optimal to recruit them.
Whereas the effect of the SDF-1:CXCR4 axis on stem cell homing is well demonstrated by the study of Tang et al, 7 the effect of the SDF-1:CXCR4 axis on myocardial response to therapy is not addressed. There are several lines of evidence that support the hypothesis that the temporal alignment of the SDF-1:CXCR4 axis improves myocardial repair and functional response. We have previously shown that surviving cardiac myocytes in the infarct border zone begin to express CXCR4 36 to 48 hours after myocardial infarction and that the level of expression increases through 96 hour. 5 However, as schematized in the Figure, this upregulation of cardiac myocyte CXCR4 expression occurs at a time of declining myocardial SDF-1 expression. With that said, we and others have demonstrated that the sustained expression of SDF-1 following myocardial infarction leads to decreased cardiac myocyte death and improved cardiac function. 8 Thus, the temporal alignment of SDF-1 and cardiac myocyte CXCR4 expression leads to improved cardiac function. How has this alignment been shown to be achievable?
• Mesenchymal stem cells express SDF-1; thus their engraftment could sustain myocardial SDF-1 levels in the infarct border zone to a time at which cardiac myocytes express CXCR4. 8, 10 • Ischemic preconditioning leads to the early expression of CXCR4 by cardiac myocytes. 11 • Growth factors, such as fibroblast growth factor-2, that signal through phosphatidylinositol 3-kinase can lead to synergistic upregulation of CXCR4 in the setting of hypoxia. 12, 13 This same hypothesis appears to be relevant in ischemic cardiomyopathy. Cardiac myocytes in the infarct border zone of explanted human hearts have been shown to express CXCR4. 8 The delivery of SDF-1 in the setting of ischemic cardiomyopathy has been shown to improve cardiac function. 3, 6 Similarly, the delivery of preparations of whole bone marrow mononuclear cells, but not only CD34ϩ cells, has been shown to improve cardiac function in patients left ventricular dysfunction at times remote from acute myocardial infarction. 14 A noteworthy difference between a whole bone marrow mononuclear preparation and CD34 ϩ cells is that the mesenchymal stem cells in the bone marrow mononuclear preparation express SDF-1, whereas CD34 ϩ cells do not.
Clearly the SDF-1:CXCR4 axis is not the only pathway active in stem cell based myocardial repair. Interleukin-10, 15 thymosin ␤4, 16 and non-CXCR4 effects of a variety of growth factors have all been shown to mediate myocardial repair.
With that said, as demonstrated by the study of Tang et al, 7 data from multiple laboratories, using multiple cell types over multiple years, have consistently shown that this axis is important in the biology of myocardial repair and that it can be exploited for therapeutic benefit.
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